Unione Europea - italiano - EMA (European Medicines Agency)

roche registration gmbh - obinutuzumab - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - leucemia linfocitica cronica (cll)gazyvaro in combinazione con clorambucile è indicato per il trattamento di pazienti adulti precedentemente non trattati da leucemia linfocitica cronica (cll) e con comorbidità che li rende inadatti per la dose completa di fludarabina terapia (vedere la sezione 5. linfoma follicolare (fl)gazyvaro in combinazione con la chemioterapia, seguita da gazyvaro terapia di mantenimento in pazienti ottenendo una risposta, è indicato per il trattamento di pazienti precedentemente non trattati linfoma follicolare avanzato. gazyvaro in combinazione con bendamustine seguita da gazyvaro di manutenzione è indicato per il trattamento di pazienti con linfoma follicolare (fl) che non hanno risposto o che è progredita durante o fino a 6 mesi dopo il trattamento con rituximab o contenente rituximab regime.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - obinutuzumabum - concentrato per soluzione per infusione - obinutuzumabum 1000 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 40 ml. - la leucemia linfatica cronica, linfoma follikuläres - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Unione Europea - italiano - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agenti antineoplastici - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - acalabrutinibum - capsule rigide - acalabrutinibum 100 mg, cellulosum microcristallinum silicificatum, amylum pregelificatum, carboxymethylamylum natricum a corresp. natrium max. 0.25 mg, magnesii stearas, kapselhülle: gelatina, e 172 (flavum), e 132, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - chronisch lymphatische leukämie (cll) - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemia, linfocitica, cronica, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 10 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.03 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 50 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.15 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika